99.7% PURITY LOT VL-2821-A CJC-1295 (No DAC) + Ipamorelin Blend
A growth-hormone-axis research blend combining 5 mg CJC-1295 (No DAC), a modified GRF(1-29) GHRH analog, with 5 mg Ipamorelin, a selective ghrelin-receptor agonist, supplied as a 10 mg total lyophilized vial for research into complementary growth-hormone secretagogue signaling.
- 1 × CJC-1295 (No DAC) + Ipamorelin Blend 10mg vial
- Tamper-evident flip-off cap
- Batch-tested for purity (≥99%)
- Lyophilized for stability during shipping
- Bacteriostatic water (3 mL)
About this compound
A growth-hormone-axis research blend combining 5 mg CJC-1295 (No DAC), a modified GRF(1-29) GHRH analog, with 5 mg Ipamorelin, a selective ghrelin-receptor agonist, supplied as a 10 mg total lyophilized vial for research into complementary growth-hormone secretagogue signaling.
- 10 mg total lyophilized blend per vial (5 mg + 5 mg)
- CJC-1295 (No DAC) — modified GRF(1-29) GHRH analog
- Ipamorelin — selective ghrelin/GH-secretagogue receptor agonist
- Synthetic peptides, ≥99% purity
- Studied for complementary GHRH + secretagogue pathway signaling
Why the lot matters
- Synthesized and tested per lot, never as a production-run average
- Certificate of Analysis published before the lot goes on sale
- Independent lab, contractually separate from manufacturing
What "research use only" means
This product is sold exclusively for in-vitro laboratory research. It is not evaluated by any medicines agency and is not intended for human or animal administration, diagnosis, treatment, or prevention of disease.
Technical data
Current lot snapshot
Shipping
Reported use in research
This product combines two synthetic growth-hormone-secretagogue peptides in a single vial: CJC-1295 without DAC (Modified GRF(1-29)), a short-acting analog of growth-hormone-releasing hormone (GHRH), and Ipamorelin, a selective agonist of the ghrelin/growth-hormone-secretagogue receptor. In preclinical research models the two peptides are studied for their action on distinct but complementary pathways governing growth-hormone release — GHRH-receptor activation and ghrelin-receptor activation, respectively. Investigators examine such combinations to explore whether co-stimulation of both pathways produces additive or synergistic effects on pulsatile growth-hormone secretion in laboratory systems. Ipamorelin is frequently included in these studies for its reported selectivity, showing minimal influence on cortisol and prolactin in research models. The blend is used strictly as a reference tool in in-vitro and animal growth-hormone-axis research.
Reported findings
Research reports that GHRH analogs such as Modified GRF(1-29) and selective secretagogues such as Ipamorelin each stimulate growth-hormone release through their respective receptors in animal research models, and that co-administration of a GHRH analog with a ghrelin-receptor agonist has been associated with greater growth-hormone release than either peptide alone in preclinical studies. Investigators attribute this to the engagement of two complementary signaling pathways. Studies of Ipamorelin describe growth-hormone elevation with minimal accompanying changes in cortisol or prolactin, a selectivity of interest when interpreting combined-secretagogue data. Findings for the individual components remain confined to laboratory and animal research contexts, and results for any specific blend ratio are model-dependent.
Handling & safety
The safety and toxicological profile of this peptide blend has not been characterized, and comprehensive data for the combination are not available. It should be handled only by qualified personnel using appropriate personal protective equipment and standard laboratory practices. This material is supplied strictly for in-vitro and preclinical research and is not for human or veterinary use. Avoid inhalation, ingestion, and contact with skin or eyes, and dispose of it in accordance with institutional guidelines.
Reconstitution
Recommended ratio
- 1 mL of bacteriostatic water per 10 mg vial
- Equivalent to 10 mg/mL (i.e. 1 mg per 10 units on a 100 U insulin syringe)
- Remove the plastic flip-off lid from the vial.
- Disinfect the rubber stoppers with alcohol wipes.
- Inject the diluent slowly down the inner wall of the vial to avoid foaming.
- Gently swirl the vial (never shake). Let it dissolve for about 10 minutes.
Storage
Unopened / before reconstitution
- Store at a stable temperature.
- Stable for 24 months.
- For long-term storage (2+ years), store at -20 °C.
Reconstituted solution
- Must be kept refrigerated.
- Avoid exposure to light and excessive heat.
3RD-PARTY LAB
| Parameter | Method | Result | Status |
|---|---|---|---|
| Identity confirmation | Mass spectrometry | Consistent with - | PASS |
| Purity | HPLC (area %) | 99.7% | PASS |
| Net peptide content | Gravimetric | 9.98 mg | PASS |
| Appearance | Visual | White to off-white lyophilized powder | PASS |
| Residual solvents | GC headspace | Within limits | PASS |
| Microbial screening | Sterility panel | No growth detected | PASS |
3RD-PARTY LAB
| Parameter | Method | Result | Status |
|---|---|---|---|
| Identity confirmation | Mass spectrometry | Consistent with - | PASS |
| Purity | HPLC (area %) | 99.6% | PASS |
| Net peptide content | Gravimetric | 9.98 mg | PASS |
| Appearance | Visual | White to off-white lyophilized powder | PASS |
| Residual solvents | GC headspace | Within limits | PASS |
| Microbial screening | Sterility panel | No growth detected | PASS |
| Lot | Filled | Purity | Report | Status | |
|---|---|---|---|---|---|
| VL-2821-A | Jul 2026 | 99.7% | TR-88621 | Active | |
| VL-2802-B | May 2026 | 99.6% | TR-88568 | Sold out |
